Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04746963 · ClinicalTrials.gov registry record · Phase 1
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
A Phase 1 study, sponsored by AsclepiX Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04746963 is a Phase 1 study that was terminated before completion, run by AsclepiX Therapeutics. The registered enrollment target is 3 participants.
The verdict
NCT04746963, a Phase 1 study, was terminated before completion, sponsored by AsclepiX Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18 subjects (up to 6 subjects per dose) with nAMD.
Interventions
- DRUG AXT107 0.1 mg
- DRUG AXT107 0.25 mg
- DRUG AXT107 0.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2022-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04746963
The ClinicalTrials.gov registry entry for NCT04746963 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AsclepiX Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AXT107 0.1 mg is the first listed.
NCT04746963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04746963 about?
NCT04746963 is a clinical study titled "Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration". This is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18 subjects (up to 6 subjects per dose) with nAMD.
What is the current status of trial NCT04746963?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-02-01. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT04746963?
The interventions under investigation include: AXT107 0.1 mg (DRUG), AXT107 0.25 mg (DRUG), AXT107 0.5 mg (DRUG).
Who is sponsoring clinical trial NCT04746963?
This trial is sponsored by AsclepiX Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.